{
    "clinical_study": {
        "@rank": "89252", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase I trial to determine the effectiveness of monoclonal antibody in treating\n      patients with recurrent gliomas."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas", 
        "completion_date": {
            "#text": "April 2001", 
            "@type": "Actual"
        }, 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Assess the toxic effects of intracystic administration of iodine-131-labeled\n      anti-tenascin monoclonal antibody 81C6. II. Identify any objective therapeutic responses to\n      this treatment in patients with recurrent cystic anaplastic gliomas.\n\n      OUTLINE: Radioimmunotherapy. Iodine-131-Labeled Anti-Tenascin Monoclonal Antibody 81C6,\n      131I-81C6.\n\n      PROJECTED ACCRUAL: Three to six patients will be entered at each dose studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed supratentorial anaplastic glioma with a\n        recurrent cyst requiring aspiration for symptom control Measurable cystic lesion confirmed\n        by contrast-enhanced CT or MRI At least 3 months since radiotherapy to site of measurable\n        disease unless unequivocal evidence of tumor progression Neoplastic cell reactivity with\n        tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a\n        monoclonal murine antibody\n\n        PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%\n        Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater\n        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 1.5 times normal\n        Alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL\n        Other: Negative pregnancy test Effective contraception required of fertile women\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n        since antineoplastic chemotherapy unless unequivocal evidence of tumor progression\n        Endocrine therapy: Corticosteroids allowed if at lowest possible dose and dose stable for\n        at least 10 days prior to entry Radiotherapy: See Disease Characteristics Surgery: Not\n        specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002753", 
            "org_study_id": "CDR0000064689", 
            "secondary_id": [
                "DUMC-1965-98-12R7", 
                "DUMC-1752-96-12R5", 
                "DUMC-1775-95-12R4", 
                "DUMC-1860-97-12R6", 
                "NCI-H96-0008"
            ]
        }, 
        "intervention": {
            "intervention_name": "iodine I 131 monoclonal antibody 81C6", 
            "intervention_type": "Radiation"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "childhood supratentorial ependymoma", 
            "recurrent childhood brain tumor", 
            "recurrent adult brain tumor", 
            "adult glioblastoma", 
            "adult anaplastic astrocytoma", 
            "adult myxopapillary ependymoma", 
            "adult anaplastic ependymoma", 
            "adult anaplastic oligodendroglioma", 
            "adult mixed glioma", 
            "adult ependymoblastoma", 
            "recurrent childhood cerebral astrocytoma", 
            "recurrent childhood ependymoma", 
            "adult giant cell glioblastoma", 
            "adult gliosarcoma"
        ], 
        "lastchanged_date": "February 15, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DUMC-1965-98-12R7"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS", 
        "overall_official": {
            "affiliation": "Duke Cancer Institute", 
            "last_name": "Darell D. Bigner, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002753"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1991", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {
        "Duke Comprehensive Cancer Center": "35.994 -78.899"
    }
}